Just looking back. March 3017 Neuren announced positive results for Rett's P2 girls 5-15. Subsequent MC was around $130m.
So, what should it be now?
About half that I suppose, because all that has occurred since is a paltry half baked deal with a US pharma for fully funded Rett's P3, millions in potential milestones, potential royalties from US, rare disease voucher, oh, and still retain total ROW rights for the drug. But, they have to repeat the P2 results for that and all they have to work with is knowledge gained from the P2. And hardly worth mentioning more potential millions in funding of Fragile X along the same lines. Forget about only increasing Orphan disease designation from 2 to 5 conditions with convincing pre-clinical results in 3 other autism spectrum conditions with their follow up drug. Not worth a crumpet really because the @#$% trial is going to be delayed by a bit. Let's get outta here into something less risky .... yeah, wait a minute, but where?
NEU Price at posting:
$1.11 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)